Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business
Key takeaways
- A copy of the letter is available to download here.
- In its first-quarter 2026 investor letter, Diamond Hill Capital Large Cap Strategy highlighted Abbott Laboratories (NYSE:ABT).
- Diamond Hill Capital Large Cap Strategy stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 investor letter:
Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business Soumya Eswaran Tue, May 26, 2026 at 6:51 PM GMT+7 3 min read ABT Diamond Hill Capital, a First Eagle Investment Management company, issued its Q1 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy declined 2.39% (net of fees), trailing the Russell 1000 Value Index’s 2.10%. The performance was positively affected by stock selection in industrials and consumer discretionary, along with an underweight in communication services. While stock selection in information technology, financials, and health care was the largest detractor from relative performance. The war in Iran is creating uncertainty in markets. However, it effectively supported the portfolio’s focus on oil-sensitive exploration and production companies. Technology companies are under pressure in Q1 amid concerns about AI s potential negative effects on their businesses, but their competitive advantages remain stronger than their current valuations suggest. Despite these challenges, the market is beginning to expand into more attractive opportunities, especially in defensive sectors and cyclicals that do not benefit from AI. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Diamond Hill Capital Large Cap Strategy highlighted Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and manufacturers medical devices, diagnostics and nutritional products. On May 22, 2026, Abbott Laboratories (NYSE:ABT) closed at $87.77 per share. One-month return of Abbott Laboratories (NYSE:ABT) was -5.81%, and its shares lost 33.43% over the past 52 weeks. Abbott Laboratories (NYSE:ABT) has a market capitalization of $152.88 billion.
Diamond Hill Capital Large Cap Strategy stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 investor letter: